Press Releases

SonaCare Medical Holds its Fourth Annual User Group Meeting

Charlotte, NC Nov 07, 2019 – SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to report on the successful conclusion of its Fourth Annual User Group Meeting held in Charlotte, N.C. on October 4-5, 2019.    

Sixty-five (65) urologists, radiologists, nurses, and technical support persons from 6 countries gathered to discuss their clinical experience with Sonablate in the imaging and treatment of prostate disease.  The 21 presentations included clinical study reports from users from around the globe, including ones on salvage treatments s/p radiation therapy and partial gland ablation and individual case reports presented by experienced users that highlighted some of the unique challenges that can face a new user of the technology.  Technical presentations were given on how to incorporate MpMRI and ultrasound/MRI fusion into the treatment paradigm as well as how to use advanced contrast imaging techniques to follow-up on results immediately post-treatment.  Extensive discussions were had on how to extend the reach of focused ultrasound ablation even further into the treatment of prostate disease, and attendees were treated to advance exposure to where SonaCare Medical plans on taking its technology next.  New this year were product presentations by Koelis, Blue Earth Diagnostics, and Focal Healthcare, who helped sponsor the event.

“It is always a treat to spend time with the enthusiastic users of our technology, and is especially rewarding to meet firsthand new urologists who have joined the ranks of those who offer the benefits of our technology to a growing number of men with prostate disease,” commented Dr. Mark Carol, CEO of SonaCare Medical.  “This year for the first time we had multiple participants from as far away as South America and Southeast Asia who contributed not only to the discussion but to the presentations.  I always come away from these meetings with new appreciation about how our technology is used and how it works, and with new ideas about how to improve its performance and its global reach.  I am already looking forward to our next gathering of these dedicated and experience healthcare practitioners.”

Since Sonablate® received FDA clearance on October 09, 2015, more than 1,800 patients have had a Sonablate HIFU prostate procedure across the 40+ locations in the U.S., including top-tier academic institutions in California, Indiana, Oklahoma, Maryland, New York, Arizona, and Texas. Over 70 U.S. physicians now offer HIFU prostate tissue ablation to their patients as a minimally invasive alternative to surgery or radiation.

Sonablate® has 510(K) clearance in the U.S. and is indicated for the transrectal high intensity focused ultrasound (HIFU) ablation of prostatic tissue. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.


SonaCare Medical is a world leader in minimally invasive focused ultrasound technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S.; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 50 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit


SonaCare Medical, LLC

Gwen Ross (704) 805-1887, This email address is being protected from spambots. You need JavaScript enabled to view it.


The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

1Guillaumier S, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol (2018),

2Stabile et al. “Medium -term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer”. BJU 12 Feb 2019

3Johnston MJ et al. Urology. 2019 Aug 23 (19)30730-7. Focal High-intensity Focused Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom.”

4Bass et al. Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. 2019; 201:113-119

Latest News

27 January 2021

20 January 2021

Connect With Us

Copyright © 2021 Sonacare Medical

Design & Development By Medtech Momentum


(888) 874-438410130 Perimeter Pkwy, Suite 250 Charlotte, NC 28216